<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03338218</url>
  </required_header>
  <id_info>
    <org_study_id>HC-G-H-1505</org_study_id>
    <nct_id>NCT03338218</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of a 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Trauma Patients</brief_title>
  <acronym>TETHYS</acronym>
  <official_title>Pragmatic, Prospective, Randomized, Controlled, Double-blind, Multi-centre, Multinational Study on the Safety and Efficacy of a 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Trauma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Society of Anaesthesiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the safety of a 6% Hydroxyethylstarch (HES) solution
      (Volulyte 6%) versus an electrolyte solution (Ionolyte) in trauma patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint of 90 day mortality and 90 day renal failure defined as biomarker increase as defined by AKIN stage 2 or RIFLE injury stage or need for RRT at any time during the first 3 month.</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine (SCr)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin-C</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine output</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Renal Replacement Therapy (RRT)</measure>
    <time_frame>90 days</time_frame>
    <description>Days on RRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International norm ratio (INR)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay in ICU</measure>
    <time_frame>90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Hypovolemia</condition>
  <arm_group>
    <arm_group_label>Volulyte 6%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volulyte 6% solution for infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ionolyte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ionolyte solution for infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Volulyte 6%</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Volulyte 6%</arm_group_label>
    <other_name>Hydroxyethylstarch 130</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ionolyte</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Ionolyte</arm_group_label>
    <other_name>Ionolyte Electrolyte Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Male or female adult patients ≥18 and ≤ 80 years of age. Women of child bearing
             potential must test negative on standard pregnancy test (urine or serum) (as soon as
             possible during emergency care)

          -  Patients with blunt or penetrating trauma suffering from estimated blood loss of ≥ 500
             ml

          -  Initial surgery deemed necessary within 24 hrs after trauma

          -  Deferred signed written informed consent form or as locally required

          -  No signs of intracranial or cerebral haemorrhage

          -  Base excess &lt; - 4 mEq/l

          -  Administration of less than 15 ml/kg body weight colloid between trauma injury and
             hospital admission.

        Exclusion:

          -  Hypersensitivity to the active substances or to any of the other excipients of the
             Investigational Products

          -  Body weight ≥ 140 kg

          -  Patients expected to die within 24h after traumatic injury

          -  Sepsis

          -  Burns

          -  Renal impairment (AKIN stage ≥ 1) or acute and/or chronic Renal Replacement Therapy

          -  Critically ill patients (typically admitted to the intensive care unit)

          -  Hyperhydration

          -  Pulmonary oedema

          -  Dehydration

          -  Hyperkalaemia

          -  Severe hypernatraemia

          -  Severe hyperchloraemia

          -  Severely impaired hepatic function

          -  Congestive heart failure

          -  Severe coagulopathy

          -  Organ transplant patients

          -  Metabolic alkalosis

          -  Simultaneous participation in another interventional clinical trial (drugs or medical
             devices studies)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang F. Buhre, Prof. Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology and Pain Management, Maastricht University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Manager</last_name>
    <phone>+49-5661-71-0</phone>
    <email>studies@bbraun.com</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hydroxyethylstarch (HES)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

